Natera stock gets Japan approval for Signatera expansion

Published on 10/05/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock is valued at USD 410.35 after Japan approved Signatera for bladder cancer use. Second-quarter revenue rose 37.7 percent to USD 752.75 million.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) stock closed at USD 410.35 on Nasdaq on October 2, 2026, after Japan approved its Signatera test for use in muscle-invasive bladder cancer. The regulatory decision gives Natera a second Japanese authorization for Signatera, while the commercial launch is planned for the first half of 2027 pending reimbursement and pricing, according to Natera on September 22, 2026.

Japan approval broadens Signatera

The approval allows Signatera to support treatment decisions involving adjuvant atezolizumab for patients with muscle-invasive bladder cancer. Natera said the decision followed data from the IMvigor011 phase III trial and marked Signatera's second authorization from Japan's Pharmaceuticals and Medical Devices Agency in three months.

The Japanese launch is a future commercial milestone rather than an immediate revenue contribution. Final reimbursement and pricing remain important because they will determine how quickly the approval translates into test volume and sales.

Revenue beats expectations in Q2

Natera reported second-quarter 2026 revenue of USD 752.75 million, up 37.7 percent from the prior-year quarter, according to MarketBeat. Adjusted loss was USD 0.47 per share, beating the USD 0.49 consensus loss by USD 0.02.

The quarter also showed the tension in the growth story: gross profit was USD 485.19 million and GAAP net loss was USD 66.97 million, based on Natera's quarterly financial statements for Q2 2026. Revenue growth is advancing faster than profitability, keeping reimbursement, pricing and operating leverage central to the valuation discussion.

Analyst targets trail the stock

Guggenheim raised its Natera price target to USD 475 from USD 360 and maintained a Buy rating on October 1, 2026, according to Markets Insider. The target lies 15.7 percent above the October 2 price.

MarketBeat lists a Moderate Buy consensus from 23 analysts, with an average target of USD 341.55, a high target of USD 475.00 and a low target of USD 172.00. That average lies 16.8 percent below the stock price, highlighting how the recent valuation has moved ahead of much of the published analyst range.

Stock remains near yearly high

Natera stock traded between USD 401.00 and USD 413.36 on October 2, 2026, and finished 3.99 percent below its 52-week high of USD 427.47. The company had a market capitalization of USD 59.2 billion and trading volume of 2,156,455 shares on that session.